Role of P2Y Receptors in Platelet Extracellular Vesicle Release

Aleksandra Gąsecka, Sylwester Rogula, Ceren Eyileten, Marek Postuła, Miłosz J. Jaguszewski, Janusz Kochman, Tomasz Mazurek, Rienk Nieuwland, Krzysztof J. Filipiak

Research output: Contribution to journalReview articleAcademicpeer-review

20 Citations (Scopus)

Abstract

Platelet extracellular vesicles (PEVs) are potential new biomarkers of platelet activation which may allow us to predict and/or diagnose developing coronary thrombosis before myocardial necrosis occurs. The P2Y1 and P2Y12 receptors play a key role in platelet activation and aggregation. Whereas the P2Y1 antagonists are at the preclinical stage, at present, the P2Y12 antagonists are the most effective treatment strategy to prevent stent thrombosis after percutaneous coronary intervention. Despite an increasing number of publications on PEVs, the mechanisms underlying their formation, including the role of purinergic receptors in this process, remain an active research field. Here, we outline the clinical relevance of PEVs in cardiovascular disease, summarize the role and downstream signalling of P2Y receptors in platelet activation, and discuss the available evidence regarding their role in PEV formation.
Original languageEnglish
Article number6065
Pages (from-to)1-14
Number of pages14
JournalInternational journal of molecular sciences
Volume21
Issue number17
DOIs
Publication statusPublished - 1 Sept 2020

Keywords

  • Antiplatelet therapy
  • Clopidogrel
  • Extracellular vesicles
  • P2Y1 receptors
  • P2Y12 receptors
  • Ticagrelor

Cite this